Lung adenocarcinoma
Conditions
Interventions
EGFR-Mutated Group:None
EGFR-Wild Type Group:None
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathological diagnosis (the "gold standard" and fundamental basis for confirming lung cancer): A definitive diagnosis requires obtaining tumor tissue through methods such as needle biopsy, bronchoscopy, thoracoscopy, or surgery, followed by histopathological examination to confirm primary lung cancer. 2. Pathological classification: It is essential to clearly distinguish between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). For non-small cell lung cancer, further specification as adenocarcinoma is required. 3. Molecular pathological diagnosis (key to guiding precision treatment for advanced lung cancer): (1) Genetic testing: Perform driver gene testing, including but not limited to EGFR, ALK, ROS1, etc., to guide subsequent targeted therapy. (2) Immune marker testing: Detect PD-L1 expression levels to guide the application of immunotherapy. 4. Thirty-eight cases were evaluated for treatment efficacy according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) after four cycles of EGFR-TKI therapy, and follow-up CYFRA21-1 data were obtained after the four cycles.
Exclusion criteria
Exclusion criteria: 1.Uncertain Pathological Diagnosis: Exclude cases without histopathologically confirmed diagnosis, or those diagnosed as "non-small cell lung cancer-not otherwise specified (NOS)," to ensure that the study subjects have confirmed lung adenocarcinoma (including specific subtypes such as lepidic, acinar, etc.). 2.Missing Data on Key Variables: Exclude cases with missing clinical staging information (preventing stage stratification) or those with severely incomplete follow-up records (making survival time incalculable). 3.Interference from Treatment History: If the study focuses on treatment-naive patients, exclude patients who underwent surgery after neoadjuvant therapy (preoperative chemotherapy/radiotherapy). If the study focuses on the efficacy of targeted drugs, exclude patients who have previously received treatment with that specific targeted drug. 4.Comorbidity with Other Malignant Tumors: Exclude patients with a history of, or currently suffering from, other primary malignant tumors, to avoid difficulties in attributing the cause of death or treatment choices. 5.Severe Comorbidities: Although difficult to completely exclude in retrospective studies, typically exclude cases of perioperative (within 30 days) death (if studying postoperative survival), or exclude cases with missing and untraceable Eastern Cooperative Oncology Group (ECOG) performance status scores. 6.Multiple Primary Cancers or Uncertain Origin of Metastasis: Exclude cases with multiple pulmonary nodules where it is impossible to determine whether they are multiple primary tumors or intrapulmonary metastases. If necessary, exclude cases with insufficient biopsy tissue that prevents differentiation between primary lung adenocarcinoma and metastatic cancer to the lung.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS);Progression-Free Survival (PFS); | — |
Countries
China
Contacts
Public ContactShan Jinlu
Army Medical Center of PLA
Outcome results
None listed